Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting
UTRECHT, The Netherlands, 2016-04-15 23:09 CEST (GLOBE NEWSWIRE) --
Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), today announced a scheduled poster presentation at the American Association for Cancer Research (AACR) 2016 Annual Meeting being held April 16-20, 2016 in New Orleans.
Merus will be presenting interim clinical data for its lead bispecific antibody candidate MCLA-128 from a first-in-human Phase 1/2 clinical trial. MCLA-128 is a novel full-length Immunoglobulin G (IgG) bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) that is designed to bind to human epidermal growth factor receptors, HER2 and HER3, present on a variety of solid tumor cells. Merus will present on the open-label dose escalation phase (Part 1) of the Phase 1/2 clinical trial. The primary objectives in Part 1 of the clinical trial are to determine a maximum tolerated dose and to establish the recommended dose for a Phase 2 clinical trial of MCLA-128; the secondary objectives are to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity.
“We believe the interim data we are presenting from Part 1 of this first clinical trial of MCLA-128 demonstrates a favorable safety profile and early signs of anti-tumor activity,” said Setareh Shamsili, MD, PhD, Chief Medical Officer of Merus. “In Part 2 of this clinical trial, we will continue to evaluate MCLA-128 for safety and efficacy in patients with selected tumor types and patients with HER2 amplification in other tumor types. We expect to report top-line data from both parts of this trial in the first half of 2017.”
“We are proud to have reached this milestone for the company, the MCLA-128 program and our Biclonics platform,” commented Ton Logtenberg, PhD, Chief Executive Officer of Merus. “The timely delivery of this clinical milestone follows the rapid progression of MCLA-128 through preclinical discovery and manufacturing, which we believe validates the strength of the Biclonics platform. We look forward to the next part of this clinical trial while we continue to use the Biclonics platform to build a pipeline of therapeutics that we believe has the potential to address the unmet needs of cancer patients.”
The details for the poster presentation are as follows:
Poster Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2/HER3, in Patients with Solid Tumors
Date & Time: Monday, April 18, 2016, 1:00 PM – 5:00 PM CDT
Abstract Number: CT050
Session ID: PO.CT01.01. Phase 1 Clinical Trials 1
Location: Section 13
Summary: In Part 1, the dose escalation phase of this Phase 1/2 clinical trial, patients with advanced solid tumors that are relapsed or refractory to at least one prior regiment of available standard treatment or for whom no curative therapy is available were enrolled. MCLA-128 was administered every 3 weeks (q3w) as an intravenous infusion over 60-120 minutes. Toxicities were assessed at escalating dose levels. Twenty-eight patients received MCLA-128 in 9 dose escalation cohorts (in a range of 40 mg to 900 mg flat dose).
A maximum tolerated dose was not reached at the dose level of 900 mg. The cumulative safety and available PK data, along with the aid of a PK simulation study, were used to support a recommended dose for a Phase 2 clinical trial of 750 mg q3w, administered over 120 minutes. We believe encouraging signs of anti-tumor activity (assessed by RECIST v.1.1) were observed. Three patients remain in the trial to date, including one metastatic non-small cell lung cancer patient who is experiencing an ongoing partial response after more than 9 months, one metastatic gastroesophageal junction cancer patient with stable disease after more than 5 months, and one metastatic colorectal cancer patient with stable disease after more than 6 months. In addition, one metastatic breast cancer patient with stable disease received 5 months of MCLA-128 treatment before disease progression. MCLA-128 was well-tolerated with a favorable safety profile in patients with advanced tumors treated at doses up to 900 mg q3w. The expansion phase (Part 2) of the clinical trial is ongoing at the recommended Phase 2 dose of 750 mg q3w, enrolling patients with selected tumor types with HER2 amplification.
About Merus B.V.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus’ second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Shelley Margetson - email@example.com
+31 (0)30 253 8800
Eliza Schleifstein - firstname.lastname@example.org
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41 | Pressemelding
TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of
eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30 | Pressemelding
SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with
Marcus Hiles - Texas Takes #1 Four Years in a Row in America's Top States for Business19.7.2018 23:39 | Pressemelding
DALLAS, July 19, 2018 (GLOBE NEWSWIRE) -- The future business scene in Texas is looking brighter than ever as the state continues to hold its place as a national leader. Growth is spreading across areas such as North Texas, Houston and San Antonio with businesses quickly expanding their operations in the state that offers some of the best in business-friendly climates and overall growth potential. Tapping into the market recently are global leaders such as Toyota, Liberty Mutual and JP Morgan who have taken advantage of the state's increasing network of commercial properties, workforce and business resources. Named by CNBC for the fourth consecutive year as America's Top State for Business, Texas scored above all 50 states on overall business competitiveness. With the business hub building on its role as a national leader for the past decade, this top rank title reflects the progress Texas has made in cementing its place in the global economy. "This national recognition comes without s
Second Quarter 2018 Results Conference Call19.7.2018 21:34 | Pressemelding
AURORA, Ontario, July 19, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) SECOND QUARTER 2018 RESULTS CONFERENCE CALL WEDNESDAY - AUGUST 8th, 2018 7:30 AM ET DIAL IN NUMBERS North America Toll Free: International Toll: Webcast: 1-888-223-4641 1-416-981-9080 www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until August 15, 2018 North America Toll Free: International Toll: Reservation No.: 1-800-558-5253 1-416-626-4100 21892829 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations email@example.com, 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations firstname.lastname@example.org, 905-726-7108 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originali
Uganda National Airlines Company Limited Signs Firm Order for Four Bombardier CRJ900 Aircraft19.7.2018 18:36 | Pressemelding
First operator of the new CRJ Series ATMOSPHÈRE cabin in Africa MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that it has signed a firm order for four new CRJ900 regional jets with Uganda National Airlines Company. Based on the list price for the CRJ900 aircraft, the firm order is valued at approximately US$190 million. "We congratulate the Government of Uganda for the revival of its national flag carrier, and are thrilled that the new airline has selected Bombardier and the CRJ900 regional jets for its upcoming debut," said Jean-Paul Boutibou, Vice President, Sales, Middle-East and Africa, Bombardier Commercial Aircraft. "Recognized for its superior economics and efficiency, the CRJ Series aircraft have enabled airlines worldwide to serve communities with better connectivity, and we look forward to supporting the development of Uganda's regional air travel with these CRJ900 regional jets." Uganda Airlines will operate the CRJ900 in dual-cla
CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology19.7.2018 15:03 | Pressemelding
"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies" SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL). The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models wil
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom